Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) gapped up prior to trading on Friday . The stock had previously closed at $19.23, but opened at $20.30. Nuvectis Pharma shares last traded at $19.1150, with a volume of 11,819 shares.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright increased their price target on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. UBS Group set a $33.00 price objective on shares of Nuvectis Pharma in a research report on Monday, July 6th. Weiss Ratings downgraded Nuvectis Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Roth Capital increased their price objective on Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Finally, Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Nuvectis Pharma currently has a consensus rating of “Hold” and a consensus price target of $35.00.

Nuvectis Pharma Stock Performance

The firm’s 50-day simple moving average is $18.16 and its 200 day simple moving average is $12.23. The company has a market cap of $622.28 million, a P/E ratio of -14.58 and a beta of -0.26.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). As a group, research analysts forecast that Nuvectis Pharma, Inc. will post -0.98 earnings per share for the current year.

Insider Transactions at Nuvectis Pharma

In related news, CEO Ron Bentsur bought 12,500 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the transaction, the chief executive officer owned 3,688,424 shares of the company’s stock, valued at $73,768,480. This represents a 0.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Marlio Charles Mosseri purchased 50,000 shares of the stock in a transaction dated Tuesday, June 30th. The stock was bought at an average cost of $18.32 per share, with a total value of $916,000.00. Following the completion of the purchase, the insider owned 3,186,576 shares in the company, valued at $58,378,072.32. The trade was a 1.59% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 28.55% of the stock is currently owned by company insiders.

Institutional Trading of Nuvectis Pharma

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Nuvectis Pharma during the second quarter worth about $18,414,000. Vanguard Group Inc. boosted its holdings in shares of Nuvectis Pharma by 4.8% in the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock valued at $4,206,000 after buying an additional 31,903 shares during the period. Occam Crest Management LP increased its position in shares of Nuvectis Pharma by 31.0% during the fourth quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock worth $2,869,000 after acquiring an additional 90,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Nuvectis Pharma by 11.8% during the fourth quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after acquiring an additional 38,291 shares during the period. Finally, State Street Corp lifted its position in Nuvectis Pharma by 13.1% in the 4th quarter. State Street Corp now owns 154,666 shares of the company’s stock valued at $1,168,000 after acquiring an additional 17,950 shares in the last quarter. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.